Shining a light on intestinal traffic
dc.contributor.author | Murphy, Carola T. | |
dc.contributor.author | Nally, Kenneth | |
dc.contributor.author | Shanahan, Fergus | |
dc.contributor.author | Melgar, Silvia | |
dc.contributor.editor | McCafferty, Donna-Marie | |
dc.contributor.funder | Science Foundation Ireland | en |
dc.contributor.funder | Higher Education Authority | en |
dc.contributor.funder | European Commission | en |
dc.contributor.funder | GlaxoSmithKline, United Kingdom | en |
dc.date.accessioned | 2012-07-18T14:25:00Z | |
dc.date.available | 2012-07-18T14:25:00Z | |
dc.date.issued | 2012-01 | |
dc.date.updated | 2012-07-18T10:46:07Z | |
dc.description.abstract | Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is associated with enhanced leukocyte infiltration to the gut, which is directly linked to the clinical aspects of these disorders. Thus, leukocyte trafficking is a major target for IBD therapy. Past and emerging techniques to study leukocyte trafficking both in vitro and in vivo have expanded our knowledge of the leukocyte migration process and the role of inhibitors. Various strategies have been employed to target chemokine- and integrin-ligand interactions within the multistep adhesion cascade and the S1P/S1PR1 axis in leukocyte migration. Though there is an abundance of preclinical data demonstrating efficacy of leukocyte trafficking inhibitors, many have yet to be confirmed in clinical studies. Vigilance for toxicity and further research is required into this complex and emerging area of IBD therapy. | en |
dc.description.sponsorship | Science Foundation Ireland (02/CE/B124; 07/CE/B1368) | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Published Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | Carola T. Murphy, Kenneth Nally, Fergus Shanahan, and Silvia Melgar, “Shining a Light on Intestinal Traffic,” Clinical and Developmental Immunology, vol. 2012, Article ID 808157, 14 pages, 2012. doi:10.1155/2012/808157 | en |
dc.identifier.doi | 10.1155/2012/808157 | |
dc.identifier.issn | 1740-2522 | |
dc.identifier.issn | 1740-2530 | |
dc.identifier.journaltitle | Clinical and Developmental Immunology | en |
dc.identifier.startpage | 808157 | en |
dc.identifier.uri | https://hdl.handle.net/10468/634 | |
dc.identifier.volume | 2012 | en |
dc.language.iso | en | en |
dc.publisher | Hindawi Publishing Corporation | en |
dc.relation.uri | http://www.hindawi.com/journals/cdi/2012/808157/ | |
dc.rights | Copyright © 2012 Carola T. Murphy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. | en |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | en |
dc.subject | IBD | en |
dc.subject | Leukocyte infiltration | en |
dc.subject | Leukocyte trafficking inhibitors | en |
dc.subject.lcsh | Inflammatory bowel diseases--Treatment | en |
dc.subject.lcsh | Gastrointestinal system--Diseases | en |
dc.subject.lcsh | Crohn’s disease--Treatment | en |
dc.subject.lcsh | Ulcerative colitis--Treatment | en |
dc.subject.lcsh | Leucocytes | en |
dc.title | Shining a light on intestinal traffic | en |
dc.type | Article (peer-reviewed) | en |